CD40 antibody

Catalog No. ABIN2660521

This anti-CD40 antibody is a Hamster Monoclonal antibody detecting CD40 in FACS. Suitable for Mouse.

Quick Overview for CD40 antibody (ABIN2660521)

Target: CD40

Reactivity: Mouse

Host: Hamster

Clonality: Monoclonal

Conjugate: This CD40 antibody is un-conjugated

Application: Flow Cytometry (FACS)

Clone: HM40-3

Product Details anti-CD40 Antibody

Purity: This antibody is at > 85 % purity.

Isotype: IgM kappa, IgM

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for CD40

Target: CD40

Alternative Name: CD40

Background: CD40 is a 48 kD type I transmembrane glycoprotein, also known as Bp50. It is a member of the tumor necrosis factor receptor (TNFR) superfamily, expressed on B cells, basal epithelial cells, macrophages, follicular dendritic cells, endothelial cells, and a subset of CD34+ hematopoietic progenitors. CD40 regulates B cell development/maturation, Ig isotype switching and, in combination with other signals such as IL-4, protects B cells from surface Ig-induced apoptosis and promotes proliferation. Interaction of CD40 with its ligand CD154 (gp39) expressed on activated T cells, is important in costimulation and immune regulation. The HM40-3 antibody has been reported to stimulate dendritic and B cell proliferation and block CD40-CD40L interactions.

Pathways: NF-kappaB Signaling, Cellular Response to Molecule of Bacterial Origin, M Phase, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints